Concerns about the ALIFE2 trial - Authors' reply

Affiliations

¹ Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK; University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK. Electronic address: s.quenby@warwick.ac.uk.
² Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK; University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK.
³ Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.
⁴ Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
⁵ Centre for Reproductive Medicine, Department of Obstetrics and Gynaecology, Amsterdam Reproduction and Development Research Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.
⁶ Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands; Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam, Netherlands; Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.

Comment

Siobhan Quenby et al. Lancet. 2024.

. 2024 Jan 20;403(10423):248.

doi: 10.1016/S0140-6736(23)02336-X.

¹ Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK; University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK. Electronic address: s.quenby@warwick.ac.uk.
² Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK; University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK.
³ Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.
⁴ Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
⁵ Centre for Reproductive Medicine, Department of Obstetrics and Gynaecology, Amsterdam Reproduction and Development Research Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.
⁶ Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands; Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam, Netherlands; Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.

No abstract available

Comment on

Concerns about the ALIFE2 trial.
Fan BE. Fan BE. Lancet. 2024 Jan 20;403(10423):245-246. doi: 10.1016/S0140-6736(23)02337-1. Lancet. 2024. PMID: 38245241 No abstract available.
Concerns about the ALIFE2 trial.
Yanagisawa R, Fujiwara SI, Sato T. Yanagisawa R, et al. Lancet. 2024 Jan 20;403(10423):246-247. doi: 10.1016/S0140-6736(23)02339-5. Lancet. 2024. PMID: 38245242 No abstract available.
Concerns about the ALIFE2 trial.
Grandone E, Brenner B, Piazza G. Grandone E, et al. Lancet. 2024 Jan 20;403(10423):246. doi: 10.1016/S0140-6736(23)02338-3. Lancet. 2024. PMID: 38245243 No abstract available.
Concerns about the ALIFE2 trial.
Tang LV, Cheng ZP, Hu Y. Tang LV, et al. Lancet. 2024 Jan 20;403(10423):247. doi: 10.1016/S0140-6736(23)02342-5. Lancet. 2024. PMID: 38245244 No abstract available.